Efficacy and safety of linagliptin in persons with Type2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study

Diabetic Medicine

Volumn 28, Issue 11, 2011, Pages 1352-1361

  Owens, D R ^a   Swallow, R ^b   Dugi, K A ^c   Woerle, H J ^c  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b BOEHRINGER INGELHEIM LTD   (United Kingdom)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Linagliptin; Metformin; Sulphonylurea; Type2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PURINES; QUINAZOLINES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053072352     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03387.x     Document Type: Article

References (30)

1. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
2. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
3. Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B et al. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive18). Diabet Med 2009; 26: 1214-1249.
4. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
5. Nathan DM, Buse JB, Davidson MB, Ferranini E, Holman RR, Sherwin R et al. Medical management of hyperglycaemia in type2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
6. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009; 49: S16-S29.
7. St Onge EL, Miller SA, Taylor JR. Novel approaches to the treatment of type2 diabetes. J Pharm Pract 2009; 22: 320-332.
8. Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008; 10: 931-938.
9. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type2 diabetes. Curr Med Res Opin 2009; 25: 2401-2411.
10. Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10: 1212-1220.
11. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-182.
12. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI1356, an inhibitor of dipeptidyl peptidase4, in healthy male volunteers. J Clin Pharmacol 2008; 48: 1171-1178.
13. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type2 diabetes. Expert Opin Investig Drugs 2010; 19: 133-140.
14. Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009; 30: 422-436.
15. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-678.
16. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-658.
17. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K et al. Linagliptin (BI1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type2 diabetes. Diabet Med 2010; 27: 1409-1419.
18. Kanada S, Watada H, Hayashi N, Sarashina A, Taniguchi A, Horie Y et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of BI1356 (proposed tradename ONDERO), a dipeptidyl peptidase4 inhibitor, in Japanese patients with type2 diabetes. Diabetes 2008; 57: A158-A159.
19. 1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-174.
20. 1c Assay. Global harmonization of hemoglobin A1c. Clin Chem 2005; 51: 681-683.
21. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). J Am Med Assoc 1999; 281: 2005-2012.
22. Del Prato S, Barnett A, Huismann H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type2 diabetes: a randomised controlled trial. Diabetes Obes Metab 2011; 13: 258-267.
23. Gomis R, Espadero R-M, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-661.
24. Taskinen M-R, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type2 diabetes: a randomised, double-blind, placebo controlled study. Diabetes Obes Metab 2011; 13: 65-74.
25. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies. Viewpoints on the way to consensus. Diabetes Care 2009; 32: S223-S231.
26. Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med 2009; 121: 40-45.
27. Deter DM. How incretin-based therapies address the spectrum of physiologic disturbance in type2 diabetes. Internet J Acad Phys Assist 2010; 8: 1.
28. Blonde L. Current antihyperglycemic treatment strategies for patients with type2 diabetes mellitus. Cleve Clin J Med 2009; 76: S4-S11.
29. Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type2 diabetes mellitus. Endocr Pract 2010; 16: 588-599.
30. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010; 27: 309-317.